[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632623":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":32,"centralContacts":36,"locations":11,"responsibleParty":42,"collaborators":11,"id":44,"slug":11,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":11,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":11,"enrollmentInfo":52,"targetDuration":11,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":69,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":11},{"fullName":5,"class":6},"Nurix Therapeutics, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: NX-5948","EXPERIMENTAL",null,[13],"Drug: NX-5948",{"label":15,"type":10,"description":11,"interventionNames":16},"Arm B: Pirtobrutinib",[17],"Drug: Pirtobrutinib",[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","NX-5948","Administered orally once daily",[9],[25],"Bexobrutideg",{"type":20,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Pirtobrutinib","Administered orally once daily per prescribing information",[15],[31],"JAYPIRCA",[33],{"name":34,"affiliation":5,"role":35},"Study Director","STUDY_DIRECTOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":11,"email":41},"Additional Site Contact Information","CONTACT","415-417-3418","clinicaltrials@nurixtx.com",{"type":43,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100632623",false,"NCT07516093","Study of NX-5948 Versus Pirtobrutinib in R\u002FR CLL\u002FSLL","A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed\u002FRefractory (R\u002FR) Chronic Lymphocytic Leukemia (CLL)\u002FSmall Lymphocytic Lymphoma (SLL)","Key Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n* Adequate organ and bone marrow function\n* Confirmed diagnosis of CLL\u002FSLL that meets iwCLL 2018 criteria for diagnosis and systemic treatment\n* Received at least one prior line of therapy for CLL\u002FSLL that included a cBTKi and must have documented disease progression during treatment with, or after discontinuation of, the cBTKi\n* Participants with SLL must have measurable disease by computed tomography (CT) per iwCLL\n\nKey Exclusion Criteria:\n\n* Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment\n* Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment\n* Ongoing systemic corticosteroids ≥10 mg\u002Fday prednisone or equivalent\n* Previously treated with a BTK degrader or a noncovalent BTKi\n* Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment\n* Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment\n\nNote: Other Inclusion\u002FExclusion criteria may apply as defined in the protocol.","ALL","18 Years",{"count":53,"type":54},620,"ESTIMATED","INTERVENTIONAL",[57],"PHASE3","The study will evaluate the efficacy and safety of NX-5948 (bexobrutideg) versus pirtobrutinib in participants with relapsed\u002Frefractory (R\u002FR) chronic lymphocytic leukemia (CLL)\u002Fsmall lymphocytic lymphoma (SLL) who are relapsed or refractory to prior covalent Bruton tyrosine kinase inhibitor (cBTKi) treatment.",[60,61,62],"B-cell Lymphoma","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma",[64,65,66,67,68,25,27],"Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)","Degrader","B-cell malignancy","BTKi","NOT_YET_RECRUITING","2026-04-06",{"date":72,"type":73},"2026-04-08","ACTUAL",{"date":75,"type":54},"2026-06",{"date":77,"type":54},"2032-06",{"name":5,"class":6}]